|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 19, 2011 ) Boca Raton, FL --- Treating kidney failure is a tedious and ongoing process, and often the only thing that keeps a person alive until a kidney donor becomes available. To assist a failing kidney in doing its job, Hemodialysis, or more commonly know as dialysis, uses a machine called a dialyzer to clean the blood. This is done by accessing a vein or artery to allows the blood to flow through the dialyzer. The dialyzer then cleans the blood before returning it to the patientÂ’s body.
However, this must occur three to four times a week in most cases, and each session can last between two and four hours. Repeated needle sticks at this frequency would destroy a personÂ’s veins. Therefore, medical technology must assist us with this process.
Artegraft provides patients with a natural collagen vascular graft which is implanted prior to treatment to create vein access. Collagen fibers are tightly woven together to create a very flexible and compliant, small tube that fastens to a vein and artery together to create a stable opening for dialysis treatment.
Artegraft was the first vascular graft approved by the FDA in 1970 and has been in continuous clinical use ever since. While their grafts are predominantly used for hemodialysis treatment, Artegraft is also approved for use, distal to the aorta, for segmental bypass, arterial replacement, patch graft, and femoropopliteal bypass when the patientÂ’s saphenous is absent or inadequate.
About Artegraft
Artegraft, Inc. was incorporated in January, 1993, upon the divestiture of the bovine vascular graft business from Johnson & Johnson. Grafts are available in lengths from 15 to 50cm and in 6, 7 and 8mm diameters.
Artegraft is positioned in the market as a biological alternative to synthetic grafts, particularly ePTFE, a thermoplastic that was never designed to be punctured 312 times per year as a hemodialysis graft. ArtegraftÂ’s natural collagen matrix, as well as its surgical versatility and compliance, has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula.
To learn more about Artegraft, please visit http://artegraft.com.
About 21st Century Health
21st Century Health is an award winning targeted business show that is independently produced by Multi-Media Productions. The show provides its business viewers an in depth opportunity to find solutions to the industry problems from some of the top business leaders from across the world. Each exclusive segment is taped in our state of the art South Florida Studio.
Once selected, companies are able to present their story and solutions to industry problems in an exclusive way that sets their company apart from the others. With more than 6,000 companies participating on over 600 shows, 21st Century Health continues to be the premier and targeted outlet for the latest business stories.
21st Century Health airs on various national cable networks that are viewed by over 100 million viewers nationwide as well as internationally via DirecTV and Dish Network. The show can also be viewed through video on demand via http://www.21chtv.com. The 21CHTV Series is also available at more than 27 prestigious college universities, including Carnegie Mellon University, Howard University, Dartmouth College and Georgetown University.
For specific market-by-market air dates and times, please e-mail Moniqueh@mmpusa.com. For more information, please visit http://www.21chtv.com.
Multi-Media Productions USA
Susan Waters
561-988-9449
swaters@mmpusa.com 
Source: EmailWire.com
|
|
|
|
